Lu Yu

机构：Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University · ORCID：0000-0002-1271-126X

发表论文 40 篇 · 总被引 222 次 · h-index 9

代表论文

• JAK2 inhibitor ameliorates the progression of experimental autoimmune myasthenia gravis and balances Th17/Treg cells via regulating the JAK2/STAT3-AKT/mTOR signaling pathway (2023 · International Immunopharmacology · 被引 28)
• Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients (2020 · Clinical Immunology · 被引 22)
• Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses (2021 · International Immunopharmacology · 被引 18)
• Targeting HIF-1α alleviates the inflammatory responses and rebuilds the CD4+ T cell subsets balance in the experimental autoimmune myasthenia gravis inflammation model via regulating cellular and humoral immunity (2023 · Life Sciences · 被引 13)
• Recurrent miscarriage and low-titer antiphospholipid antibodies (2024 · Clinical Rheumatology · 被引 12)
• Analysis of Pregnancy Outcomes in Patients Exhibiting Recurrent Miscarriage With Concurrent Low‐Titer Antiphospholipid Antibodies (2024 · American Journal of Reproductive Immunology · 被引 10)